Cancer-associated carbohydrate antigens for clinical diagnostic markers--its effectiveness and limitations.

Cancer cells express various aberrant glycoconjugates. Several kinds of carbohydrate antigens have been used for the serological tumor markers. In particular, the serological level of sialylated carbohydrate antigens, which contain the sialic acid residue in their structure, showed effectiveness in diagnosing cancer behavior. Although large number of carbohydrate antigens in serum of cancer patients was elevated broadly in various cancers, each tumor marker has different sensitivity and specificity for each cancer. Therefore, the combined use of several tumor markers which have different characteristics is effective for better sensitivity in diagnosing cancer behavior. The mechanism of synthesizing cancer-associated carbohydrate antigens is not fully understood because it is very complex. In addition, new cancer-associated carbohydrate antigens are also identified by molecular oncological studies. Those investigations are considered to develop more effective tumor markers to diagnose cancer behavior.

[1]  M. Oka,et al.  Expression of mucin 1 possessing a 3′‐sulfated core1 in recurrent and metastatic breast cancer , 2015, International journal of cancer.

[2]  Daniel Reitz,et al.  Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer , 2015, Journal of Clinical Pathology.

[3]  D. Grootendorst,et al.  CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. , 2014, Clinical colorectal cancer.

[4]  Y. Suh,et al.  The Value of Postoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 Levels for the Early Detection of Gastric Cancer Recurrence after Curative Resection , 2014, Journal of gastric cancer.

[5]  Y. Murakami,et al.  Elevated perioperative serum CA 19‐9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma , 2014, Journal of surgical oncology.

[6]  H. Yamaue,et al.  Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma , 2014, Journal of hepato-biliary-pancreatic sciences.

[7]  Jianjun Gao,et al.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer. , 2014, World journal of gastroenterology.

[8]  R. Bristow,et al.  The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[9]  I. Endo,et al.  A novel scoring system for arterial invasion of pancreatic body and tail cancer based on multidetector row computed tomography and biomarkers. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[10]  Jianjun Gao,et al.  Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China , 2013, Liver Cancer.

[11]  M. Páez de la Cadena,et al.  Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer , 2013, BMC Cancer.

[12]  J. Ahn,et al.  Implications of Different CA 15-3 Levels according to Breast Cancer Subtype at Initial Diagnosis of Recurrent or Metastatic Breast Cancer , 2012, Oncology.

[13]  Sudhir Srivastava,et al.  Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.

[14]  M. Makuuchi,et al.  Clinical and molecular insights into the hepatocellular carcinoma tumour marker des‐γ‐carboxyprothrombin , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[15]  J. Taylor‐Papadimitriou,et al.  ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. , 2011, Frontiers in bioscience.

[16]  M. Bidziński,et al.  Clinical Significance of Serum CA-125 and Soluble Tumor Necrosis Factor Receptor Type I in Cervical Adenocarcinoma Patients , 2010, International Journal of Gynecologic Cancer.

[17]  Wei Tang,et al.  Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers. , 2009, Bioscience trends.

[18]  Kazuro Furukawa,et al.  Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: downregulation of ST6GalNAc VI in renal cancers. , 2007, The Biochemical journal.

[19]  M. Makuuchi,et al.  Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues. , 2007, Hepato-gastroenterology.

[20]  L. D. Cas,et al.  Serum levels of different tumour markers in patients with chronic heart failure , 2005, European journal of heart failure.

[21]  M. Makuuchi,et al.  Histochemical expression of sialoglycoconjugates in carcinoma of the papilla of Vater. , 2005, Hepato-gastroenterology.

[22]  J. Kihlberg,et al.  Role of the Human ST6GalNAc-I and ST6GalNAc-II in the Synthesis of the Cancer-Associated Sialyl-Tn Antigen , 2004, Cancer Research.

[23]  R. Bresalier,et al.  Mucins and mucin binding proteins in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[24]  T. Ando,et al.  Synthesis of Disialyl Lewis a (Lea) Structure in Colon Cancer Cell Lines by a Sialyltransferase, ST6GalNAc VI, Responsible for the Synthesis of α-Series Gangliosides* , 2003, Journal of Biological Chemistry.

[25]  M. Makuuchi,et al.  Association of histochemical expression of Maackia amurensis leukoagglutinin‐positive glycoconjugates with behaviour of human gastric cancer , 2003, Histopathology.

[26]  K. Arisawa,et al.  Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. , 2002, Anticancer research.

[27]  R. Goodlad,et al.  Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. , 2001, Glycobiology.

[28]  H. Satoh,et al.  Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  K. Krause,et al.  Quantitative lectinhistochemical and immunohistochemical studies on the occurrence of alpha(2,3)‐ and alpha(2,6)‐linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features , 1995, Cancer.

[30]  M. Sakamoto,et al.  Serum and tissue measurements of CA72-4 in ovarian cancer patients. , 1993, Gynecologic oncology.

[31]  M. Inoue,et al.  Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors , 1992 .

[32]  R. Hamazoe,et al.  CA72-4 compared with carcinoembryonic antigen as a tumour marker for gastric cancer. , 1992, European journal of cancer.

[33]  S. Kawa,et al.  Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA50. , 1991, Scandinavian journal of gastroenterology.

[34]  S. Kawa,et al.  Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. , 1991, British Journal of Cancer.

[35]  E. Cooper,et al.  An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease. , 1990, British Journal of Cancer.

[36]  J. Verweij,et al.  The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Kitagawa,et al.  Usefulness of a new tumor marker, span‐1, for the diagnosis of pancreatic cancer , 1990, Cancer.